News

Targeted Oncology11d
FDA Actions in Oncology: April 2025 Approvals and Designations
A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...
A new era in cancer therapies is at hand
The cells targeted the cancer and eradicated it. Thirteen years later, Whitehead is still cancer-free. Since then, however, ...
Patient with rare cancer finds hope in a Memorial Healthcare clinical trial
A Davie mom fighting a rare and rapidly spreading cancer is enrolled in a pioneering clinical trial at Memorial Cancer ...
FDA grants accelerated approval to avutometinib, defactinib combination
On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...
PMLive1d
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...
PharmExec4d
FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...